NasdaqGS:KPTI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$783.2m

Last Updated

2021/06/23 04:08 UTC

Data Sources

Company Financials +

Executive Summary

Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. More Details


Snowflake Analysis

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has Karyopharm Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KPTI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: KPTI's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

4.0%

KPTI

-0.6%

US Biotechs

-0.1%

US Market


1 Year Return

-43.8%

KPTI

19.7%

US Biotechs

39.0%

US Market

Return vs Industry: KPTI underperformed the US Biotechs industry which returned 20% over the past year.

Return vs Market: KPTI underperformed the US Market which returned 39% over the past year.


Shareholder returns

KPTIIndustryMarket
7 Day4.0%-0.6%-0.1%
30 Day12.5%3.9%2.6%
90 Day-2.1%8.6%8.0%
1 Year-43.8%-43.8%21.4%19.7%41.2%39.0%
3 Year-38.8%-38.8%12.2%7.5%62.4%52.3%
5 Year49.6%49.6%60.0%47.3%132.3%106.2%

Long-Term Price Volatility Vs. Market

How volatile is Karyopharm Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Karyopharm Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: KPTI ($10.57) is trading below our estimate of fair value ($53.36)

Significantly Below Fair Value: KPTI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: KPTI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: KPTI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KPTI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KPTI has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Future Growth

How is Karyopharm Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

58.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KPTI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KPTI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KPTI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KPTI's revenue (32.6% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: KPTI's revenue (32.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KPTI's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Karyopharm Therapeutics performed over the past 5 years?

-14.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KPTI is currently unprofitable.

Growing Profit Margin: KPTI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KPTI is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.

Accelerating Growth: Unable to compare KPTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KPTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: KPTI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Karyopharm Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: KPTI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: KPTI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: KPTI has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: KPTI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KPTI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KPTI has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 17% each year.


Dividend

What is Karyopharm Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KPTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KPTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KPTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KPTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KPTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Richard Paulson (53 yo)

0.083

Tenure

US$1,131,596

Compensation

Mr. Richard A. Paulson, M.B.A. serves as Director at Karyopharm Therapeutics Inc. since February 26, 2020 and serves as its Chief Executive Officer & President since May 3, 2021. He had been Chief Executiv...


Leadership Team

Experienced Management: KPTI's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: KPTI's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: KPTI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.


Top Shareholders

Company Information

Karyopharm Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Karyopharm Therapeutics Inc.
  • Ticker: KPTI
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$783.215m
  • Shares outstanding: 75.09m
  • Website: https://www.karyopharm.com

Number of Employees


Location

  • Karyopharm Therapeutics Inc.
  • 85 Wells Avenue
  • 2nd Floor
  • Newton
  • Massachusetts
  • 2459
  • United States

Listings


Biography

Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment o...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/23 04:08
End of Day Share Price2021/06/22 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.